Therapy Areas: Oncology
First Patient with HER2-Overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform
21 September 2021 - - The first patient has been dosed with US-based clinical-stage company Triumvira Immunologics Triumvira's investigational T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, in development for the treatment of HER2-overexpressing cancers, the company said.

Triumvira's TAC01-HER2, which harnesses natural T cell activation, was manufactured on Lonza's proprietary Cocoon Platform at C3i Center Inc in Montréal, Canada.

The Cocoon Platform is an automated and closed platform for patient-scale cell therapy manufacturing, designed to overcome manufacturing challenges associated with patient-scale personalized medicines.

This collaboration aims to bring novel immunotherapies to patients for the treatment of HER2-overexpressing cancers.

The Cocoon Platform will enable manufacturing efficiencies, robustness, and cost reductions by decreasing the necessary manpower, time, and space requirements and ultimately allow the delivery of potentially curative cellular immunotherapies to more patients, at a higher quality and for a reduced cost.

From the start of the collaboration, Triumvira's TAC-T cell treatment was efficiently translated to Lonza's Cocoon Platform, involving technology transfer to C3i and engineering runs, to support an investigational new drug submission in under a year.

The TAC01-HER2 clinical trial is actively enrolling patients across numerous clinical study sites in the US.

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases.

Founded in 1897 in the Swiss Alps, Lonza operates across five continents.

Triumvira Immunologics, Inc. is a clinical-stage company developing unique, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with liquid and solid tumors.

Its proprietary T cell Antigen Coupler technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor therapies. Triumvira is headquartered in Austin, Texas with research facilities in Hamilton, Ontario.

C3i Center Inc. is a unique Canadian organization that accelerates the development of cancer immunotherapies and cellular therapies by providing a one-stop-shop for commercialization across the continuum of product development.


Related Headlines